Close this search box.

Boston Pharma names Margaret Koziel CMO

ARTICLE | Management Tracks

Plus: Phillip Dennis joins I-Mab as CMO, and an update from Exscientia

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

June 7, 2024 12:51 AM UTC

Boston Pharmaceuticals Inc. hired Margaret Koziel as CMO, succeeding acting CMO Juan Carlos Lopez-Talavera, who will become an adviser. Koziel was CMO at Innoviva Inc. (NASDAQ:INVA) and Axcella Health Inc. (NASDAQ:AXLA). Boston’s most advanced program is BOS-580, a FGF21 analogue, for metabolic dysfunction-associated steatohepatitis (MASH).

Cancer play I-Mab (NASDAQ:IMAB) hired Phillip Dennis as CMO, effective June 17. Dennis was VP of lung cancer strategy and global project head for an antibody-drug conjugate at Sanofi (Euronext:SAN; NASDAQ:SNY)…